Josh Schimmer Analyst PerformanceBiotech Equity Research Analyst at Cantor FitzgeraldJosh Schimmer is a stock analyst at Cantor Fitzgerald in the healthcare sector, covering 27 publicly traded companies. Over the past year, Josh Schimmer has issued 31 stock ratings, including buy and hold recommendations. While full access to Josh Schimmer's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Josh Schimmer's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings44 Last 8 YearsBuy Recommendations90.70% 39 Buy RatingsCompanies Covered27 Unique Companies Ratings Distribution43RatingsDistribution of strong buy, buy, hold, and sell ratings by Josh Schimmer.RatingPercentageCount Strong Buy0.0%0 ratings Buy90.7%39 ratings Hold9.3%4 ratings Sell0.0%0 ratingsOut of 43 total stock ratings issued by Josh Schimmer at Cantor Fitzgerald, the majority (90.7%) have been Buy recommendations, followed by 9.3% Hold.Best & Worst CallsBest Call0000.0%TRVIJul 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%RCKTMay 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ27 companiesJosh Schimmer, an analyst at Cantor Fitzgerald, currently covers 27 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare27 companies100.0%Josh Schimmer of Cantor Fitzgerald specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY19 companies70.4%PHARMACEUTICALS8 companies29.6% Josh Schimmer's Ratings History at Cantor Fitzgerald Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsNBIXNeurocrine Biosciences7/31/2026Boost Price Target$166.71$215.00Overweight$0.0000.00% ROICRNXCrinetics Pharmaceuticals7/7/2026Downgrade$42.03Hold$0.0000.00% ROINUVLNuvalent6/9/2026Downgrade$122.89Neutral$0.0000.00% ROISPRYARS Pharmaceuticals5/28/2026Boost Price Target$8.50$30.00Overweight$0.0000.00% ROIARTVArtiva Biotherapeutics5/26/2026Reiterated Rating$7.87Overweight$0.0000.00% ROIARTVArtiva Biotherapeutics5/11/2026Boost Price Target$11.27$40.00Overweight$0.0000.00% ROICABACabaletta Bio5/4/2026Reiterated Rating$2.94$30.00Overweight$0.0000.00% ROISEPNSepterna3/10/2026Reiterated Rating$28.61$60.00Overweight$0.0000.00% ROIASNDAscendis Pharma A/S3/2/2026Reiterated Rating$234.75$324.00Outperform$0.0000.00% ROIRCKTRocket Pharmaceuticals2/27/2026Boost Price Target$5.24$10.00Overweight$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. NUVLNuvalent2/27/2026Boost Price Target$103.03$140.00Overweight$0.0000.00% ROIJANXJanux Therapeutics2/27/2026Lower Price Target$13.51$100.00Overweight$0.0000.00% ROIRNAAvidity Biosciences12/18/2025Set Price Target$72.12$72.00$0.0000.00% ROIRNAAvidity Biosciences12/18/2025Downgrade$72.14Hold$0.0000.00% ROIMIRMMirum Pharmaceuticals12/8/2025Reiterated Rating$67.18$130.00Overweight$0.0000.00% ROIJANXJanux Therapeutics12/2/2025Lower Price Target$33.99$150.00Overweight$0.0000.00% ROIDMACDiaMedica Therapeutics11/14/2025Initiated Coverage$5.42Overweight$0.0000.00% ROIPVLAPalvella Therapeutics11/6/2025Boost Price Target$79.51$200.00Overweight$0.0000.00% ROIMIRMMirum Pharmaceuticals11/5/2025Boost Price Target$72.38$95.00Overweight$0.0000.00% ROIXENEXenon Pharmaceuticals11/4/2025Reiterated Rating$39.68$55.00Overweight$0.0000.00% ROICABACabaletta Bio10/31/2025Boost Price Target$2.72$30.00Overweight$0.0000.00% ROIBBIOBridgeBio Pharma10/30/2025Boost Price Target$65.44$110.00Overweight$0.0000.00% ROITRMLTourmaline Bio10/29/2025Reiterated Rating$47.98Overweight$0.0000.00% ROINUVLNuvalent10/15/2025Initiated Coverage$84.66$135.00Overweight$0.0000.00% ROIIVVDInvivyd10/6/2025Initiated Coverage$1.16$10.00Overweight$0.0000.00% ROIRNAAvidity Biosciences9/22/2025Lower Price Target$42.34$65.00Outperform$0.0000.00% ROICGONCG Oncology9/8/2025Reiterated Rating$32.81$75.00Overweight$0.0000.00% ROIDNLIDenali Therapeutics9/8/2025Reiterated Rating$15.37Overweight$0.0000.00% ROISEPNSepterna9/5/2025Reiterated Rating$14.44$25.00Overweight$0.0000.00% ROICABACabaletta Bio9/5/2025Reiterated Rating$1.61$15.00Overweight$0.0000.00% ROIRCKTRocket Pharmaceuticals8/8/2025Lower Price Target$2.90$8.00Overweight$0.0000.00% ROIBBIOBridgeBio Pharma7/29/2025Reiterated Rating$46.59$95.00Overweight$00.0000.00% ROITRVITrevi Therapeutics7/1/2025Initiated Coverage$5.47$25.00Overweight$00.0000.00% ROICMPSCompass Pathways6/23/2025Reiterated Rating$2.46$6.00In-Line$00.0000.00% ROIRCKTRocket Pharmaceuticals5/16/2025Boost Price Target$6.50$30.00Overweight$0.0000.00% ROIASNDAscendis Pharma A/S5/2/2025Boost Price Target$177.67$280.00Outperform$000.0000.00% ROICGONCG Oncology4/28/2025Reiterated Rating$30.06$75.00Overweight$00.0000.00% ROIARTVArtiva Biotherapeutics3/25/2025Lower Price Target$3.92$20.00Overweight$0.0000.00% ROIAARDAardvark Therapeutics3/10/2025Initiated Coverage$10.13$50.00Overweight$0.0000.00% ROIBBIOBridgeBio Pharma2/21/2025Reiterated Rating$37.07$95.00Overweight$00.0000.00% ROITrump’s $250 Bill – See Immediately (Ad)Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in modern history - larger than Paul Tudor Jones' Black Monday bet and Michael Burry's $700 million Big Short. While most investors chase AI stocks, insiders including Ray Dalio and Tudor Jones have quietly repositioned. The last comparable shock sent certain stocks up 2,464%, 2,778%, and even 13,000% - turning a $10,000 stake into over $1.3 million. Dr. Eifrig has identified one stock at the center of this story and released a free broadcast to help investors act before the window closes.Watch the free broadcast now and learn where to position your moneyKRYSKrystal Biotech2/20/2025Reiterated Rating$187.60$215.00Overweight$000.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupThe Goldman Sachs GroupWeiss RatingsCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank Aktiengesellschaft Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
